Real-world data showed reductions in healthcare resource utilization and improved glycemic control over 1 year with ...

A U.S. appeals court revived hundreds of lawsuits alleging Merck failed to warn patients about an increased risk of thigh ...

Continuous glucose monitoring, compared with fingerstick tests, was feasible and accurate in an inpatient setting among patients and nurses.

Eversense 365 is said to be the world's first one-year CGM system, offering a new long-term solution for diabetes management.

Dexcom Inc. revealed data from several studies showing significant benefits of its continuous glucose monitoring technology ...

Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management ...

New continuous glucose monitoring sensors (small sensors that penetrate the skin to measure glucose levels in real time) are ...

Dexcom unveiled its Dexcom G7 continuous glucose monitoring (CGM) for people with diabetes age two years and older in ...

Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system.

Home blood glucose monitoring was first introduced in 1980. While there were initially hurdles to overcome related to accuracy and cost, a consistent hurdle since that time has been efficient data ...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of ...

The results highlight the viability and benefits of a standardized CGM policy in enhancing inpatient diabetes management. Among the 27 nurses who completed the user experience surveys, 74% found ...